Company: SISI
Filing Date: 2025-03-13
Form Type: S-1/A
Source: 0001493152-25-010206
Chunk: 14

Company: SHINECO, INC.
Filing Date: 2025-03-13
Form: S-1/A
Chunk 14
---
 October 21, 2024, our stockholders approved a reverse stock split of the Company’s common stock, with a par value of $0.001 per share, at a ratio of not less than 1-for-2 and not more than 1-for-24, subject to the Company’s board of directors’ authority to determine the ratio, and on October 23, 2024, the board of directors of the Company approved a 1-for-24 reverse stock split of the common stock, which became effective on November 12, 2024 (the “November 2024 Reverse Stock Split”, together with the February 2024 Reverse Stock Split, the “Reverse Stock Splits”). As a result of the November 2024 Reverse Stock Split, each of the 24 pre-split shares of common stock outstanding were automatically combined and converted to one issued and outstanding share of common stock without any action on the part of the stockholders. Unless otherwise indicated, all share amounts and per share amounts in this prospectus have been adjusted to give retroactive effect to the Reverse Stock Splits for all periods presented.

| 2 |

<div align='center'>PROSPECTUS SUMMARY</div>

Our Company

Shineco is a holding company incorporated in Delaware. As a holding company with operations of its own, Shineco conducts its operations through its subsidiaries and, prior to the termination of VIE structure in September 2023, also through the former VIEs. The Company did not have any equity ownership of the former VIEs, instead it received the economic benefits of the former VIEs’ business operations through certain contractual arrangements. Shares of common stock currently listed on the Nasdaq Capital Markets are shares of our Delaware holding company. The Chinese regulatory authorities could disallow our structure, which could result in a material change in our operations and the value of our securities could decline or become worthless.

Current Business

On December 30, 2022, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life”), a company established under the laws of Hong Kong and a wholly owned subsidiary of the Company, closed the acquisition (the “Biowin Acquisition”) of 51% of the issued equity interests of Changzhou Biowin Pharmaceutical Co., Ltd. (“Biowin”), a company established under the laws of China, pursuant to the previously announced stock purchase agreement, dated as of October 21, 2022, among Beijing Kanghuayuan Medicine Information Consulting Co., Ltd.,